Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cervical cancer: targeted drug trial opens for HER2-positive patients

NCT ID NCT07051486

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tests a new drug called SHR-A1811 in 60 women with advanced cervical cancer that has come back or spread and no longer responds to standard treatments. The drug targets a protein called HER2 on cancer cells. The main goal is to see how many patients' tumors shrink. Participants must be 18-75 years old and in reasonably good health otherwise.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, 350011, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shandong University Qilu Hospital

    RECRUITING

    Jinan, Shandong, 250063, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

RECURRENT OR METASTATIC CERVICAL CANCER